Akkermansia supplementation reduces ovarian cancer progression in mice
News Release, International Society of Microbiota, France – February 13, 2023
Ovarian cancer (OC) ranks as the first common cause of gynecologic cancer death in women around the world. Yet, it remains a clinical challenge for its difficulty in early diagnosis and insensitivity to treatments.
The gut microbiota receives accumulating attention given its influence on the development of various malignanciesIt is well known that gut microbiota modulate multiple carcinoma progression through immunoregulation. However, the relationship between OC and gut microbiota has not been fully characterized.
Wang et al. utilized fecal microbiota transplantation (FMT) to explore how the gut microbiota from patients with OC influences OC progression in vivo. They reported that the feces of patients with OC demonstrate different characteristics from benign controls. After FMT from patients with OC into OC-bearing mice, the tumor development accelerates. Further, an Akkermansia supplementation with FMT significantly suppresses OC progression in mice.
They also identified the critical role of the gut microbiota in regulating the immune microenvironment to suppress OC progression. RNA sequencing of tumors showed that T cell activation pathways are upregulated after Akkermansia supplementation with FMT. Moreover, acetate accumulation accompanied Akkermansia abundance elevation, which is associated with enhanced interferon γ (IFNγ) secretion of CD8+ T cells and also its tumor-killing property.
Their work highlighted the importance of protective gut microbiome in immune surveillance of OC, which connects accumulation of acetate and the cytotoxic function of CD8+ T cells by increasing IFNγ secretion.
Targeting Microbiota 2023 will present the latest research related microbiota, cancer, and immunotherapy. Submit a related abstract.
Media contact:
International Society of Microbiota
microbiota@microbiota-ism.com
Targeting Microbiota 2023 Congress
October 18-19, 2023
Website | LinkedIn | Facebook